Protagenic Therapeutics, Inc.

The momentum for this stock is not very good. Protagenic Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Protagenic Therapeutics, Inc..
Log in to see more information.
PTIX Fundamental Data by TradingView

News

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nProtagenic Therapeutics just reported results for the second quarter of 2024.\nThe post PTIX Stock Earnings: Protagenic Therapeutics...\n more…

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nProtagenic Therapeutics just reported results for the first quarter of 2024.\nThe post PTIX Stock Earnings: Protagenic Therapeutics...\n more…

Protagenic Therapeutics files $100M mixed securities shelf
Protagenic Therapeutics files $100M mixed securities shelf

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatme
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatme

Accesswire No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential...\n more…

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

Accesswire NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose...\n more…

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nProtagenic Therapeutics just reported results for the fourth quarter of 2023.\nThe post PTIX Stock Earnings: Protagenic Therapeutics...\n more…